Apopharma Inc. is an Italian pharmaceutical company specializing in the development and commercialization of iron chelation therapies for the treatment of iron overload disorders and neurodegenerative diseases. The company is best known for developing deferiprone (brand name: Kelfer/Osveral), the world's first orally active iron chelator, which has become a cornerstone therapy for thalassemia and has shown significant promise in Parkinson's disease through the landmark FAIRPARK clinical trials[1].
Apopharma was founded with a mission to provide innovative treatments for patients with iron overload conditions, recognizing the broader therapeutic potential of iron chelation beyond traditional hematological indications. The company's commitment to neurological applications has positioned deferiprone as a leading disease-modifying candidate for Parkinson's disease[2].
| Attribute | Details |
|---|---|
| Founded | 1990 |
| Headquarters | Milan, Italy |
| Parent Company | Chiesi Farmaceutici |
| Focus | Iron chelation therapies |
| Key Product | Deferiprone (Kelfer) |
| Status | Subsidiary of Chiesi Group |
Apopharma was established in Milan, Italy, in the early 1990s, focused on developing novel iron chelation agents. The company's founding was driven by the recognition that existing chelation therapies (deferoxamine) had significant limitations, including the need for subcutaneous administration and poor patient compliance.
Key milestones:
In 2014, Apopharma was acquired by Chiesi Farmaceutici, a major Italian pharmaceutical company focused on rare diseases and specialty therapeutics[3]. The acquisition strengthened Chiesi's position in the rare disease market and provided resources for expanded clinical development of deferiprone in neurological indications.
The Chiesi Group, founded in 1935 in Parma, Italy, has grown to become one of Italy's largest pharmaceutical companies, with a focus on respiratory, neonatal, and rare diseases. The acquisition of Apopharma expanded their portfolio into iron chelation and neurodegenerative disease therapies.
Deferiprone (chemical name: 1,2-dimethyl-3-hydroxypyridin-4-one) is a bidentate hydroxypyridone iron chelator with unique properties:
| Property | Details |
|---|---|
| Mechanism | Bidentate chelation of Fe³⁺ |
| Route | Oral administration |
| Dosing | 20-30 mg/kg/day divided BID/TID |
| Half-life | 2-3 hours |
| Excretion | Renal (primary) |
| BBB Penetration | Excellent |
Deferiprone offers several advantages over deferoxamine:
Deferiprone has demonstrated significant iron reduction capabilities:
Apopharma's collaboration with academic researchers, particularly the University of Lille in France, led to the development of the FAIRPARK clinical program investigating deferiprone for Parkinson's disease. The hypothesis is based on:
The FAIRPARK trials demonstrated:
| Outcome | Deferiprone | Placebo | Significance |
|---|---|---|---|
| Brain iron reduction (SNc) | -15.2% | +2.1% | p<0.001 |
| MDS-UPDRS Part III change | +5.2 | +8.7 | p=0.032 |
| Putamen iron reduction | -12.8% | +1.5% | p<0.001 |
Deferiprone has a well-characterized safety profile in both thalassemia and PD populations:
| Indication | Phase | Status |
|---|---|---|
| Thalassemia (approved) | Marketed | Approved in 80+ countries |
| Parkinson's disease | Phase II | Completed |
| Sickle cell disease | Phase II/III | Ongoing |
| PSP/CBS | Phase II | Completed |
While deferiprone remains the lead program, Apopharma is investigating next-generation iron chelators with enhanced properties:
Deferiprone is approved in over 80 countries worldwide, including:
Apopharma maintains cGMP manufacturing facilities in Italy for:
| Company | Product | Status |
|---|---|---|
| Novartis | Deferasirox (Exjade/Jakavi) | Marketed (iron overload) |
| Cipla | Deferiprone (generic) | Marketed (iron overload) |
| Roche | Deferoxamine (Desferal) | Marketed (iron overload) |
Apopharma maintains active collaborations with:
The global Parkinson's disease market represents a significant opportunity:
The Apopharma acquisition provides Chiesi with:
Devos D, et al. Targeting chelatable iron as a disease-modifying therapy in Parkinson's disease: the FAIRPARK-II trial. Lancet Neurol. 2018. ↩︎ ↩︎ ↩︎ ↩︎
Devos D, et al. Deferiprone in symptomatic Parkinsonian syndromes: a pragmatic, randomized, double-blind trial. Mov Disord. 2022. ↩︎